Ongoing Clinical Studies

Mindstrong Health is participating in several trials selected to test the value of digital phenotyping in clinical populations.

Depression

  • Goal

    Define signals correlated with cognition, brain imaging, and mood in patients with depression and obesity undergoing psychosocial treatments.

  • n = 200

  • Completion

    Phase 1 (n = 100) 2017 Q2, Completion of Phase 2 (n = 100) 2019

  • Partner

    Stanford University (funded by NIH)

  • Goal

    Define the signals that predict recovery and relapse in depressed patients treated with ketamine.

  • n = 30

  • Completion

    2018 Q1

  • Partner

    Kadima Clinic (funded by Mindstrong)

  • Goal

    Define the signals that predict stress-induced depression in medical interns.

  • n = 550

  • Completion

    2018 Q3

  • Partner

    University of Michigan (funded by NIH)

  • Goal

    Define the signals that can serve as an outcome measure in a randomized clinical trial of a new antidepressant (Phase 2a).

  • n = 100

  • Completion

    2018 Q4

  • Partner

    Blackthorn Therapeutics (funded by Blackthorn Therapeutics)

PTSD

  • Goal

    Define the signals that predict onset of PTSD following a traumatic event.

  • n = 5000

  • Completion

    2022

  • Partner

    University of North Carolina (funded by NIH)

Serious Mental Illness

  • Goal

    Define the signals that predict re-hospitalization and ER visits in patients with depression, bipolar disorder, and schizophrenia.

  • n = 600

  • Completion

    2018 Q2

  • Partner

    Humana Health